Navigation Links
FDA Grants QT Ultrasound® Breakthrough Device Designation

Today the Food and Drug Administration (FDA) granted QT Ultrasound LLC’s Breakthrough Device designation request for its QT Scanner 2000 Model A. Unlike traditional breast imaging modalities, the company’s QTscan™ has no radiation, no injections, and no compression, potentially offering new opportunities for earlier and more frequent screening for young women at high risk for breast cancer, who have no available FDA-cleared screening options.

Women at high risk have a 20% lifetime risk of developing breast cancer.* Causes include genetic factors, family history, and exposure to radiation. With one first-degree female relative, such as a mother or sister, diagnosed with breast cancer, a woman’s risk is doubled. Women who carry a mutation in their BRCA 1 or BRCA 2 genes have a 40-85% lifetime risk of developing breast cancer and are more likely to develop breast cancer at a younger age.* While only about 7% of women with breast cancer are diagnosed before the age of 40 years, the most aggressive form of breast cancer and the worst survival rates occur in younger women.* However, routine mammograms are not recommended for women under 40 years old. Quantitative Transmission Ultrasound is an emerging trend in ultrasound technology that can see through dense breasts and uses no radiation, giving it the potential to have significant benefits for younger women at high risk. “Breast cancer screening is important for all women, but women who are at a higher risk of breast cancer may need to be screened earlier and more often than other women. We hope to provide an imaging option that is safe, comfortable, and effective.” Says Dr. John Klock, CEO and Founder of QT Ultrasound.

The proposed indications for use, as designated by the FDA as breakthrough are:
“The QT Ultrasound Breast Scanner is an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast, without emitting ionizing radiation. The device is intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer based upon genetic testing and/or other established criteria, who have not reached the age of mammography screening for their risk level in applicable breast cancer screening guidelines. Diagnostic work-up of findings may follow as clinically appropriate. The QT Scanner is not to be used as a replacement for standard screening mammography.”

The company will be working with the FDA to submit an appropriate pre-market submission. If approved, the device may be legally marketed for use as a breast cancer screening device in younger women at high risk for breast cancer.

About QT Ultrasound
QT Ultrasound® is a privately held company engaged in the research, development, and commercialization of an innovative automated breast imaging system producing high-resolution transmission ultrasound images. The company has received FDA clearance for its QTscan™, and the National Institutes of Health (NIH) awarded over $15 million in funding to continue QT Ultrasound research. The company’s clinical trials have been conducted at prestigious institutions in the US and Europe and include ongoing trials at the Marin Breast Health Trial Center in Novato, California. QTscans are now available commercially through the breast imaging centers of QTbreasthealth™.

The QT Ultrasound Breast Scanner is for use as an ultrasonic imaging system to provide reflection-mode and transmission-mode images of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.

For more information about QT Ultrasound, visit
For more information about the commercially available QTscan, visit
For more information about clinical trials, visit

American Cancer Society, Rethink Breast Cancer, NCBI

Read the full story at

Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved

Related medicine technology :

1. Bayer Awards $2 Million in Grants to Advance Hemophilia Research and Patient Care
2. WellCare Announces $20,000 in Grants to Help Reduce Tobacco Use and Promote Smoke-Free Environments in Kentucky
3. Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Spain
4. FDA Grants Orphan Drug Designation to CSRAs DynPort Vaccine Company for Plague Vaccine
5. Allergan Continues Commitment to Future of Headache Medicine with Educational Grants for Young Neurologists and Research Scientists
6. Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
7. FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Multiple Invasive Fungal and Mold Infections
8. Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin ("PedPRM") in Australia and New Zealand
9. FDA Grants Orphan Drug Designation to Debiopharm International SAs IAP Inhibitor Debio 1143 in the Treatment of Ovarian Cancer
10. Superdisintegrants Market Worth 416.5 Million USD by 2021
11. FDA Grants Second Orphan Designation For VAL-083
Post Your Comments:
(Date:3/18/2019)... ... March 18, 2019 , ... Women’s Excellence in Obstetrics and Gynecology ... each month. The March show airs Wednesday, March 20 at 7pm. , This ... at Beaumont Hospital in Royal Oak. , Special guests include Danialle Karmanos, Barb Crone, ...
(Date:3/17/2019)... ... March 17, 2019 , ... Lofta, Inc., a San Diego ... commercial agreement with Itamar Medical Ltd. which advances their revolutionary “Complete Path” home ... Itamar’s clinically validated diagnostic tool into their streamlined process. The Itamar Medical WatchPAT ...
(Date:3/15/2019)... ... March 15, 2019 , ... Dallas plastic ... of the best plastic surgeons in the country by Castle Connolly's Top Doctor ... best healthcare professionals in acknowledged medical specialties such as plastic surgery, carefully screens ...
Breaking Medicine Technology:
(Date:3/15/2019)... ... 15, 2019 , ... Strategic Mobility Group, LLC (SMG3), a ... healthcare website, Integrating a vibrant array of colors with a clean, simple ... needs. , “We are thrilled to debut our website ahead of HIMSS 2019, ...
(Date:3/15/2019)... ... March 15, 2019 , ... Matt Strickland has joined ... Technology Officer. Strickland is assuming the role following the departure of Jerad Johnson, ... he is excited to be working for GPT. “The telemedicine world seems to ...
(Date:3/14/2019)... ... 14, 2019 , ... When:    Wednesday, March 20 - 3 p.m. ... Beach Blvd., Long Beach, CA 90806 , What:    Los Angeles County Supervisor Janice Hahn ... and other partners to celebrate the start of construction of The Spark at ...
(Date:3/14/2019)... ... 2019 , ... Reset Summer Camp, one of the only summer camp programs ... of their application portal for summer 2019. In addition, the camp has ... Gilboa – popularly known as Dr. G – to oversee family engagement. , ...
(Date:3/14/2019)... ... March 13, 2019 , ... NuView Life Sciences (NVLS) subsidiary ... by Intermountain Healthcare of its proprietary in vitro prostate cancer urine test at ... is a pre-revenue oncology company that is focused on developing and commercializing in ...
Breaking Medicine News(10 mins):